Stock BHC BAUSCH HEALTH COMPANIES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Bausch Health Companies Inc. Stock Toronto S.E.

Equities

BHC

CA0717341071

Pharmaceuticals

Delayed Toronto S.E.
Other stock markets
 11:08:13 2024-04-25 am EDT 		5-day change 1st Jan Change
11.74 CAD +0.09% Intraday chart for Bausch Health Companies Inc. -0.84% +10.44%
03:07pm Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes MT
03:04pm Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes MT

Financials

Sales 2024 * 9.39B 12.86B Sales 2025 * 9.45B 12.96B Capitalization 3.14B 4.3B
Net income 2024 * 336M 461M Net income 2025 * 381M 522M EV / Sales 2024 * 2.46 x
Net Debt 2024 * 19.91B 27.28B Net Debt 2025 * 18.33B 25.12B EV / Sales 2025 * 2.27 x
P/E ratio 2024 *
13 x
P/E ratio 2025 *
8.31 x
Employees 20,270
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.66%
More Fundamentals * Assessed data

Chart Bausch Health Companies Inc.

Dynamic Chart

Latest news about Bausch Health Companies Inc.

Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes MT
Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes MT
Bausch Health in 'Stronger Position' for Bausch + Lomb Distribution, RBC Says MT
RBC Previews Bausch Health's Q1, Trims Target to US$11 MT
RBC Trims Price Target on Bausch Health to $11 From $12, Keeps Sector Perform Rating MT
RBC Cuts Bausch + Lomb Target to US$18, Reiterates Outperform, as Previews Q1 MT
Bausch Health's Issuer Credit Rating Upgraded by S&P MT
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says MT
RBC Notes "Positive" Appellate Court Ruling For Bausch Health, But Thinks Market Assigning ~32% BLCO Distribution Odds MT
Bausch wins US appeal to block Alvogen generic of diarrhea drug RE
Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan CI
TSX ends flat as gold stocks drop, mood cautious ahead of rate decision RE
Bausch Health Up Near 0.4% In US Premarket After Announcing Patent Lawsuit Against Amneal Pharmaceuticals MT
North American Morning Briefing : Inflation Data, -2- DJ
Trump eyes $43 million haul from biggest fundraiser yet RE
More news

Latest transcript on Bausch Health Companies Inc.

Logo Bausch Health Companies Inc.
Bausch Health Companies Inc., Q4 2023 Earnings Call, Feb 22, 2024
More transcripts

Analyst Recommendations on Bausch Health Companies Inc.

RBC Trims Price Target on Bausch Health to $11 From $12, Keeps Sector Perform Rating MT
Bausch Health's Issuer Credit Rating Upgraded by S&P MT
Trump eyes $43 million haul from biggest fundraiser yet RE
RBC Ups PT on Bausch Health Companies to $12 From $9 Reflecting Upcoming Appellate Court Decisions & Potential BLCO Distribution, Maintains Sector Perform Rating MT
RBC Lifts Price Target on Bausch Health to $9 From $8, Keeps Sector Perform Rating MT
More recommendations

Press releases Bausch Health Companies Inc.

Bausch Health, Canada Inc. - Acne vulgaris treatment PrARAZLO now available to patients through British Columbia PharmaCare public drug plan AQ
Bausch Health Companies - Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029 AQ
Bausch Health to Announce First-Quarter 2024 Results on May 2 AQ
Canadian Investment Regulatory Organization Trade Resumption - BHC AQ
Canadian Investment Regulatory Organization Trading Halt - BHC AQ
More press releases

News in other languages on Bausch Health Companies Inc.

Insider - Milliardäre sammelten Geld für Trumps Sicherheitsleistung
Bausch Health Companies Inc.: KORREKTUR DURCH QUELLE: Thermage(R) FLX und TR-4 Return Pad von Solta Medical erhalten Registrierungszertifikate in China
KKR : signe un accord de financement avec Bausch Health
Citadel : l'hedge da record, 16 miliardi di dollari di utili (MF)
Bolsa de Madrid: ¿Culpa o no culpa?
More news

Quotes and Performance

1 day+0.09%
1 week-0.84%
Current month-18.19%
1 month-8.92%
3 months+7.71%
6 months+23.06%
Current year+10.44%
More quotes

Highs and lows

1 week
11.54
Extreme 11.54
12.10
1 month
11.50
Extreme 11.5
15.43
Current year
10.10
Extreme 10.1
15.43
1 year
7.56
Extreme 7.56
15.43
3 years
5.10
Extreme 5.1
42.45
5 years
5.10
Extreme 5.1
43.97
10 years
5.10
Extreme 5.1
347.84
More quotes

Managers and Directors - Bausch Health Companies Inc.

Managers TitleAgeSince
Thomas Appio CEO
 Chief Executive Officer 61 -
John Barresi DFI
 Director of Finance/CFO 51 22-05-23
Mirza Dautbegovic COO
 Chief Operating Officer - -
Members of the board TitleAgeSince
Robert Power BRD
 Director/Board Member 67 08-07-31
John Paulson CHM
 Chairman 68 17-05-31
Steven Miller BRD
 Director/Board Member 35 21-03-16
More insiders

Quotes

Date Price Change Volume
24-04-25 11.74 +0.09% 64 187
24-04-24 11.73 +0.60% 195,668
24-04-23 11.66 +0.69% 245,917
24-04-22 11.58 -3.02% 288,127
24-04-19 11.94 +0.84% 255,804

Delayed Quote Toronto S.E., April 25, 2024 at 11:08 am EDT

More quotes

Company Profile

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.
Sector
Pharmaceuticals
Calendar
2024-05-01 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for Bausch Health Companies Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
8.56 USD
Average target price
10.07 USD
Spread / Average Target
+17.66%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.17% 562B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.46% 358B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.43% 322B
ABBVIE INC. Stock AbbVie Inc.
+7.25% 297B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.38% 219B
NOVARTIS AG Stock Novartis AG
+6.06% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-10.35% 196B
PFIZER, INC. Stock Pfizer, Inc.
-11.24% 149B
AMGEN INC. Stock Amgen Inc.
-6.96% 146B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BHC Stock
  4. BHC Stock